Loading...

RDHL

RDHL

REDHILL BIOPHARMA LTD

(RDHL)

2025 6-K

RHB-204 Development

30 Apr '26

Annual Financial Results

27 Apr '26

Opaganib Research Update

22 Apr '26

Nasdaq Compliance Notice

14 Apr '26

Shareholder Approval

5 Mar '26

Commercial Launch Initiated

25 Feb '26

Shareholder Meeting Notice

27 Jan '26

Extraordinary Meeting Notice

22 Jan '26

RHB-102 Progress Update

5 Jan '26

Strategic Transaction Update

31 Dec '25

Equity Purchase Agreement

23 Dec '25

Positive Opaganib Results

15 Dec '25

Compliance Regained

1 Dec '25

Funding Increase

26 Nov '25

Court Judgment Win

4 Nov '25

Nasdaq Notification

22 Oct '25

Purchase Agreement Amendment

21 Oct '25

New Deal Signed

6 Oct '25

Court Victory

29 Sep '25

Filing Update

5 Sep '25

Financial Highlights

5 Sep '25

Legal Award Update

20 Aug '25

Talicia Licensing Payments

18 Aug '25

Compliance Extension

14 Aug '25

Positive FDA Feedback

21 Jul '25

New Cancer Study

1 Jul '25

Market Purchase Agreement

25 Jun '25

Annual Meeting Outcomes

27 May '25

Warrant Exercise Completion

19 May '25

Court Win Secured

13 May '25

Meeting Postponed

5 May '25

H. Pylori Education Program

2 May '25

Patent Approval Secured

28 Apr '25

Nasdaq Notification

17 Apr '25

Weight Loss Breakthrough

16 Apr '25

2024 Financial Update

10 Apr '25

Board Resignation

8 Apr '25

Annual Shareholder Meeting

1 Apr '25

Annual Meeting Notice

26 Mar '25

UK Marketing Submission

18 Mar '25

RHB-204 Study Launch

12 Mar '25

Business Update

27 Feb '25

New Licensing Agreement

25 Feb '25

Clinical Trial Initiation

4 Feb '25

Market Offering Agreement

3 Feb '25

Talicia Coverage Expansion

21 Jan '25

Opaganib Study Results

10 Dec '24

Court Award Win

2 Dec '24

Opaganib Presentation

28 Oct '24

Collaboration Announcement

22 Oct '24

Government Funding Secured

15 Oct '24

Medi-Cal Agreement

1 Oct '24

New Patent Announcement

30 Sep '24

Shareholder Meeting Results

18 Sep '24

Meeting Adjournment

17 Sep '24

Talicia Guidelines Update

9 Sep '24

Proxy Statement Update

5 Sep '24

Compliance Regained

5 Sep '24

COVID-19 Treatment Update

3 Sep '24

Financial Update

29 Aug '24

FDA Drug Designation

26 Aug '24

Talicia Launch UAE

21 Aug '24

Positive Drug Results

19 Aug '24

ADS Ratio Change

16 Aug '24

Annual Meeting Notice

13 Aug '24

Annual Meeting Notice

6 Aug '24

Positive Study Results

1 Aug '24

Cash Balance Strengthened

22 Jul '24

License Termination

9 Jul '24

Board Resignation

6 Jun '24

New Patent Granted

3 Jun '24

New Patent Announcement

6 May '24

Patient Enrollment Update

24 Apr '24

2023 Financial Results

8 Apr '24

Stock Offering Completed

4 Apr '24

Capital Raise

3 Apr '24

Direct Offering Announcement

2 Apr '24

Share Capital Increase

21 Mar '24

Meeting Adjourned

20 Mar '24

Nasdaq Deficiency Notice

14 Mar '24

Patent Secured

11 Mar '24

Opaganib Evaluation

5 Mar '24

Share Capital Increase

20 Feb '24

Opaganib Study Results

20 Feb '24

Extraordinary Meeting Notice

13 Feb '24

Direct Offering Completed

26 Jan '24

Securities Purchase Agreement

26 Jan '24

Funding Announcement

25 Jan '24

Patent Approval

25 Jan '24

External Links:

SEC

RedHill Biopharma Ltd. reported that Mr. Eric Swenden resigned from the Board effective April 8, 2025, due to personal reasons and not due to any disagreements. The event occurred on April 7, 2025.

AI Assistant

REDHILL BIOPHARMA LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.